SLXN
Silexion Therapeutics Corp
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Under these circumstances, in accordance with the requirements of Accounting Standards Codification (“ASC”) 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.”View the 10-Q filed May 15, 2026
Company with tickers: SLXN, SLXNW
Market Cap
$9.29M
Shares Outstanding
3,330,785
CIK
2022416
CUSIP
G1281K130
13F Activity (30d)
2 filings
1 filers
Website
Visit website
Investor Relations
Investor relations
Earnings calls and other investor events (conferences, investor days) grouped as single events — the transcript and audio, plus, for earnings calls, the 8-K earnings release and the quarter's 10-Q or 10-K. Each badge shows which artefacts have landed.
| Period | Call date | Event | Artefacts | Open |
|---|---|---|---|---|
| FY2026 Q1 | 2026-05-18 | Silexion Therapeutics Corp Q1 FY2026 Earnings Call |
Audio
Transcript
Slides
8-K10-Q
|
|
| FY2025 Q3 | 2025-11-12 | Silexion Therapeutics Corp Q3 FY2025 Earnings Call |
Audio
Transcript
Slides
8-K10-Q
|
|
| FY2025 Q2 | 2025-08-12 | Silexion Therapeutics Corp Q2 FY2025 Earnings Call |
Audio
Transcript
Slides
8-K10-Q
|
|
| FY2025 Q1 | 2025-05-13 | Silexion Therapeutics Corp Q1 FY2025 Earnings Call |
Audio
Transcript
Slides
8-K10-Q
|
|
| FY2024 Q4 | 2025-03-18 | Silexion Therapeutics Corp Q4 FY2024 Earnings Call |
Audio
Transcript
Slides
8-K10-K
|
|
| FY2024 Q3 | 2024-11-14 | Silexion Therapeutics Corp Q3 FY2024 Earnings Call |
Audio
Transcript
Slides
8-K10-Q
|
Showing 1–6 of 6 earnings calls